Table 1. Randomized clinical trials of surgery for esophageal cancers with and without neoadjuvant chemotherapy.
| Reference | Trial | Treatment | Treatment cohort | Patients randomized (no.) | OS 5-yrrate (%) | Disease-free 5-yr rate (%) | R0 resection (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CS only | CS | S | CS | S | CS | S | CS | S | ||||||
| Kelsen DP, et al. (2007) (1) | North American (USA Intergroup 113) | Cisplatin + FU | Localized esophageal cancer (50/50 adenocarcinoma/epidermoid) | 216 | 227 | 20 | 20 | _ | _ | 63 | 59 | |||
| Allum WH, et al. (2009) (2) | European (OEO2) | Cisplatin + FU | Localized esophageal cancer (>60% each arm) | 400 | 402 | 23 | 17.1 | _ | _ | _ | _ | |||
| Cunningham D, et al. (2006) (3) | MAGIC | ECF | Adenocarcinoma of lower esophagus, GEJ, or stomach | 250 | 253 | 36.3 | 23 | _ | _ | 69.3 | 66.4 | |||
| Ycou M, et al. (2011) (4) | FNCLCC/FFCD Multicenter Phase III | Cisplatin + FU | Adenocarcinoma of lower esophagus, GEJ or stomach | 113 | 111 | 38 | 24 | 34 | 19 | 87 | 74 | |||
CS, neoadjuvant chemotherapy followed by surgery; ECF, epirubicin, cisplatin, and infused fluorouracil; FU, fluorouracil; OS, overall survival; S, surgery alone.